https://www.pharmaradar360.com/article/countering-motor-neuron-degeneration-with-base-editing-155eca28b20c8601PharmaRadar360en2026-09-18T12:00:00.000ZCountering Motor Neuron Degeneration with Base Editinghttps://www.pharmaradar360.com/article/establishment-of-two-new-on-site-laboratories-approved-465c999c4a9c1229PharmaRadar360en2026-09-18T12:00:00.000ZEstablishment of two new On-site Laboratories approvedhttps://www.pharmaradar360.com/article/shining-a-light-on-uterine-cancer-rising-incidence-and-mortality-persistent-ineq-b6df0ffb13807c1dPharmaRadar360en2026-09-18T11:00:17.000ZShining a Light on Uterine Cancer: Rising Incidence and Mortality, Persistent Inequitieshttps://www.pharmaradar360.com/article/bristol-myers-squibb-to-report-results-for-third-quarter-2026-on-october-29-2026-915d65a4fe2302cbPharmaRadar360en2026-09-18T10:59:00.000ZBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026https://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-9eef7f5883b17b66PharmaRadar360en2026-09-18T10:55:03.000ZExclusive-US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-e-9dda3e8e04d1e9eaPharmaRadar360en2026-09-18T10:55:00.000ZMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-ocrevus-for-children-and-adolescents-with-7987b36e70396aa4PharmaRadar360en2026-09-18T10:45:00.000ZCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosishttps://www.pharmaradar360.com/article/merck-launches-your-hive-of-whole-health-to-support-whole-person-care-for-people-6fb49d94bbe3b4f2PharmaRadar360en2026-09-18T10:45:00.000ZMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVhttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-8159bc55d8a873cePharmaRadar360en2026-09-18T10:15:47.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/nuvectis-pharma-haisco-licensing-deal-revitalises-biotech-but-no-rush-to-invest-3a916a8e5ac53c18PharmaRadar360en2026-09-18T10:15:05.000ZNuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)https://www.pharmaradar360.com/article/chicago-biotech-inomagen-lands-up-to-2-9m-for-gene-therapy-targeting-afib-2314e0a3b1c7a48dPharmaRadar360en2026-09-18T10:15:00.000ZChicago biotech Inomagen lands up to $2.9M for gene therapy targeting AFibhttps://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311PharmaRadar360en2026-09-18T10:10:17.000ZMarket Movers RX: West Pharmaceutical Services Leads Gainershttps://www.pharmaradar360.com/article/novartis-india-acquires-pfizer-s-minipress-brands-for-150-million-717f175a2a74699dPharmaRadar360en2026-09-18T10:04:35.000ZNovartis India acquires Pfizer’s Minipress brands for $150 millionhttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-outline-msa-drug-plans-at-asx-smidcaps-conf-1fca461c030238b6PharmaRadar360en2026-09-18T10:03:29.000ZAlterity Therapeutics (NASDAQ: ATHE) to outline MSA drug plans at ASX SMIDcaps conferencehttps://www.pharmaradar360.com/article/xenon-pauses-phase-3-depression-trials-after-psychosis-events-c474442598d818f4PharmaRadar360en2026-09-18T10:03:00.000ZXenon pauses phase 3 depression trials after psychosis eventshttps://www.pharmaradar360.com/article/ai-virtual-biotech-transforms-drug-discovery-6df6d3ca1fbffbc8PharmaRadar360en2026-09-18T09:59:38.000ZAI Virtual Biotech Transforms Drug Discoveryhttps://www.pharmaradar360.com/article/the-key-to-success-is-being-willing-to-understand-the-energy-system-9887c5050e48720dPharmaRadar360en2026-09-18T09:57:06.000Z‘The key to success is being willing to understand the energy system’https://www.pharmaradar360.com/article/these-blood-thinners-may-have-an-unexpected-benefit-for-alzheimer-s-patients-daa8fc27301148bfPharmaRadar360en2026-09-18T09:48:31.000ZThese blood thinners may have an unexpected benefit for Alzheimer’s patientshttps://www.pharmaradar360.com/article/cantor-fitzgerald-maintains-overweight-rating-on-ultragenyx-pharmaceutical-39-pr-90bfb8ef4162d81ePharmaRadar360en2026-09-18T09:41:18.000ZCantor Fitzgerald maintains Overweight rating on Ultragenyx Pharmaceutical, $39 price targethttps://www.pharmaradar360.com/article/novo-bets-on-ai-designed-macrocycles-in-orbis-oral-drugs-deal-3d2fb0a79abc2e12PharmaRadar360en2026-09-18T09:29:10.000ZNovo bets on AI-designed macrocycles in Orbis oral drugs dealhttps://www.pharmaradar360.com/article/grunenthal-prices-850m-euros-of-notes-to-refinance-and-fund-expansion-51639ee1c0a91b88PharmaRadar360en2026-09-18T09:24:14.000ZGrünenthal prices 850m euros of notes to refinance and fund expansionhttps://www.pharmaradar360.com/article/rapport-therapeutics-inc-rapp-stock-analysis-a-clinical-stage-biotech-with-a-49-bb04e31254be6de9PharmaRadar360en2026-09-18T09:19:49.000ZRapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potentialhttps://www.pharmaradar360.com/article/celcuity-inc-celc-stock-analysis-unpacking-an-89-32-potential-upside-in-biotech-ed1c905c6f09d8a1PharmaRadar360en2026-09-18T09:19:25.000ZCelcuity Inc. (CELC) Stock Analysis: Unpacking An 89.32% Potential Upside In Biotechhttps://www.pharmaradar360.com/article/oruka-therapeutics-inc-orka-stock-analysis-a-58-6-potential-upside-beckons-biote-d636f4afe1bf33f2PharmaRadar360en2026-09-18T09:19:23.000ZOruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investorshttps://www.pharmaradar360.com/article/oric-pharmaceuticals-oric-stock-analysis-a-60-upside-potential-with-strong-buy-r-8623ff2cd166514bPharmaRadar360en2026-09-18T09:19:20.000ZOric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotechhttps://www.pharmaradar360.com/article/primo-capital-launches-biotech-venture-fund-for-italy-s-lazio-region-b6ff7a9c7111e9f9PharmaRadar360en2026-09-18T09:09:55.000ZPrimo Capital launches biotech venture fund for Italy's Lazio regionhttps://www.pharmaradar360.com/article/a-journey-to-self-discovery-the-story-of-a-circle-u-student-fellow-5fea8b858725c8aePharmaRadar360en2026-09-18T09:06:34.000ZA journey to self discovery – the story of a Circle U. Student Fellowhttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f50b3d6ed1b0bc0dPharmaRadar360en2026-09-18T09:01:38.000ZThe Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.https://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-f0e619b6ad1a6523PharmaRadar360en2026-09-18T09:00:00.000ZThe specter of AI-enabled bioweapons is a wake-up call for biotechhttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-0fc9c2c1015a12a7PharmaRadar360en2026-09-18T08:52:31.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-f337a3e18a403d26PharmaRadar360en2026-09-18T08:52:27.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/lb-pharmaceuticals-rated-buy-with-85-base-value-150-potential-if-phase-3-succeed-9332fe094c538a69PharmaRadar360en2026-09-18T08:46:20.000ZLB Pharmaceuticals rated buy with $85 base value, $150 potential if Phase 3 succeeds by 2027https://www.pharmaradar360.com/article/mhra-consultation-on-statutory-fees-2026-4e7ecd381fcc9a03PharmaRadar360en2026-09-18T08:45:02.000ZMHRA consultation on statutory fees (2026)https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-mnov-36-pbls-10-abcl-9-hae-neo-140ed34b93773a97PharmaRadar360en2026-09-18T08:36:00.000ZBiotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEOhttps://www.pharmaradar360.com/article/boehringer-discontinues-phase-iii-easi-kidney-trial-of-vicadrostat-5d694399009054c9PharmaRadar360en2026-09-18T08:35:26.000ZBoehringer discontinues Phase III EASi-KIDNEY trial of vicadrostathttps://www.pharmaradar360.com/article/china-targets-3-5-trillion-yuan-pharmaceutical-industry-by-2030-ea3e6220b6b84bbfPharmaRadar360en2026-09-18T08:33:00.000ZChina Targets 3.5 Trillion Yuan Pharmaceutical Industry by 2030https://www.pharmaradar360.com/article/hexavalent-combination-vaccine-programme-guidance-83f6b178f952c923PharmaRadar360en2026-09-18T08:30:02.000ZHexavalent combination vaccine: programme guidancehttps://www.pharmaradar360.com/article/0366002724-ur-test-120ml-sterile-108d430e0a4ba326PharmaRadar360en2026-09-18T08:14:32.000ZΑνάκληση της παρτίδας 0366002724 του Ιατροτεχνολογικού προϊόντος UR-TEST 120ml Sterile Ουροσυλλέκτηςhttps://www.pharmaradar360.com/article/vendanges-sur-le-site-hospitalier-des-hus-de-la-robertsau-pour-les-residents-de-c010efcb07425afdPharmaRadar360en2026-09-18T08:13:19.000ZVendanges sur le site hospitalier des HUS de la Robertsau pour les résidents de l’EHPAD : héritage patrimonial et lien intergénérationnelhttps://www.pharmaradar360.com/article/a-guide-to-sarms-definition-side-effects-and-dangers-e67630b4d57afdc1PharmaRadar360en2026-09-18T08:00:59.000ZA Guide to SARMs: Definition, Side Effects, and Dangershttps://www.pharmaradar360.com/article/biomedicine-powerhouse-china-targets-quarter-of-global-first-in-class-drugs-6b7e17dcbf9db5c6PharmaRadar360en2026-09-18T08:00:06.000ZBiomedicine powerhouse: China targets quarter of global first-in-class drugshttps://www.pharmaradar360.com/article/herzmedizin-und-anatomie-beim-festival-der-wissenschaft-und-neugier-ae5897933fcd4fa9PharmaRadar360en2026-09-18T07:42:16.000ZHerzmedizin und Anatomie beim „Festival der Wissenschaft und Neugier“https://www.pharmaradar360.com/article/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-9c761ffe135492bbPharmaRadar360en2026-09-18T07:28:36.000ZTrump Administration Shift Puts This Corner of Biotech Back in Favorhttps://www.pharmaradar360.com/article/why-i-keep-going-back-to-ukraine-during-wartime-df612d9b073be5dcPharmaRadar360en2026-09-18T07:26:33.000ZWhy I keep going back to Ukraine during wartimehttps://www.pharmaradar360.com/article/millimeterarbeit-gegen-lungentumoren-die-music-studie-53be2a6ee6a105b4PharmaRadar360en2026-09-18T07:14:56.000ZMillimeterarbeit gegen Lungentumoren: die MUSIC-Studiehttps://www.pharmaradar360.com/article/pawbio-animal-health-biologics-services-1a048e6660565241PharmaRadar360en2026-09-18T07:13:03.000ZPawBio Animal Health Biologics Serviceshttps://www.pharmaradar360.com/article/tumore-al-seno-in-humanitas-torna-paziente-diplomata-e54455d5d56e61c1PharmaRadar360en2026-09-18T07:03:41.000ZTumore al seno: in Humanitas torna “Paziente diplomata”https://www.pharmaradar360.com/article/chronisch-entzundliche-darmerkrankungen-im-fokus-a1687f02fff393f7PharmaRadar360en2026-09-18T07:03:18.000ZChronisch-entzündliche Darmerkrankungen im Fokushttps://www.pharmaradar360.com/article/unmc-brings-ems-professionals-to-omaha-for-training-4f1f1a30c9c75fcbPharmaRadar360en2026-09-18T07:00:00.000ZUNMC brings EMS professionals to Omaha for traininghttps://www.pharmaradar360.com/article/insilico-medicine-s-alex-zhavoronkov-bets-china-and-ai-can-deliver-the-drug-indu-bf58fc441aef28acPharmaRadar360en2026-09-18T07:00:00.000ZInsilico Medicine's Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthroughhttps://www.pharmaradar360.com/article/anna-maria-fjordb-ge-discussed-ethnographic-findings-on-digitalisation-and-judic-741ca0d3539fbc98PharmaRadar360en2026-09-18T06:58:57.000ZAnna Maria Fjordbøge discussed ethnographic findings on digitalisation and judicial independencehttps://www.pharmaradar360.com/article/inflammation-biotech-electra-charges-up-with-350m-from-upsized-ipo-58f7ac98a3c81cd2PharmaRadar360en2026-09-18T06:58:51.000ZInflammation biotech Electra charges up with $350M from upsized IPOhttps://www.pharmaradar360.com/article/candidate-christy-knorr-tours-unmc-9c858ca4e9103a33PharmaRadar360en2026-09-18T06:58:00.000ZCandidate Christy Knorr tours UNMChttps://www.pharmaradar360.com/article/employee-giving-campaign-runs-through-sept-25-3d755fdad3d90840PharmaRadar360en2026-09-18T06:56:00.000ZEmployee Giving Campaign runs through Sept. 25https://www.pharmaradar360.com/article/dr-klepser-to-lead-session-on-culture-by-design-673f758cb628666cPharmaRadar360en2026-09-18T06:54:00.000ZDr. Klepser to lead session on ‘Culture by Design’https://www.pharmaradar360.com/article/unmc-for-the-record-sept-18-2026-26f128b25ad022fcPharmaRadar360en2026-09-18T06:50:00.000ZUNMC for the record, Sept. 18, 2026https://www.pharmaradar360.com/article/aspen-leader-shares-insights-on-advancing-healthcare-transformation-across-afric-e197406ab7edc88cPharmaRadar360en2026-09-18T06:40:19.000ZAspen leader shares insights on advancing healthcare transformation across Africahttps://www.pharmaradar360.com/article/foundationone-cdx-alk-9df8eafd03eb3fdaPharmaRadar360en2026-09-18T06:30:00.000ZFoundationOne CDx がんゲノムプロファイル、ALK融合遺伝子陽性の非小細胞肺癌に対するロルラチニブのコンパニオン診断として承認を取得https://www.pharmaradar360.com/article/chugai-obtains-approval-for-foundationone-cdx-cancer-genomic-profile-as-a-compan-a1b0d45f052647e4PharmaRadar360en2026-09-18T06:30:00.000ZChugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/otsuka-and-jolly-good-launch-new-content-for-faceduo-dementia-care-support-vr-un-2392b089dce1c64fPharmaRadar360en2026-09-18T06:00:00.000ZOtsuka and Jolly Good Launch New Content for FACEDUO Dementia Care Support VR Understanding a New Perspective on Dementiahttps://www.pharmaradar360.com/article/fete-de-la-science-2026-b279a061dcc65a5cPharmaRadar360en2026-09-18T06:00:00.000ZFête de la science 2026https://www.pharmaradar360.com/article/tissue-repair-asx-trp-phase-3-wound-healing-trial-remains-central-to-development-7287d50919577414PharmaRadar360en2026-09-18T05:55:00.000ZTissue Repair (ASX:TRP): Phase 3 Wound Healing Trial Remains Central to Development Pathhttps://www.pharmaradar360.com/article/china-unveils-15th-five-year-plan-for-pharmaceutical-industry-targeting-over-20-2ab6174a22012261PharmaRadar360en2026-09-18T05:55:00.000ZChina Unveils 15th Five-Year Plan for Pharmaceutical Industry, Targeting Over 20% Annual Revenue Growth in Innovative Drugshttps://www.pharmaradar360.com/article/flu-vaccination-in-the-social-care-sector-63cb5603bb33eecdPharmaRadar360en2026-09-18T05:45:14.000ZFlu vaccination in the social care sectorhttps://www.pharmaradar360.com/article/the-latest-iphone-apple-watch-and-airpods-lineups-arrive-in-stores-worldwide-ec905d3774ad7d98PharmaRadar360en2026-09-18T05:02:14.000ZThe latest iPhone, Apple Watch, and AirPods lineups arrive in stores worldwidehttps://www.pharmaradar360.com/article/etra-ipo-news-antibody-biotech-electra-therapeutics-prices-upsized-ipo-at-15-mid-bd92cafd24c85550PharmaRadar360en2026-09-18T04:59:00.000ZETRA IPO News - Antibody biotech Electra Therapeutics prices upsized IPO at $15 midpointhttps://www.pharmaradar360.com/article/2026-7-10-15-943b204f7d94498aPharmaRadar360en2026-09-18T04:57:29.000Z2026年度 第7回東北大学病院がんセミナー開催のお知らせ（10/15開催）https://www.pharmaradar360.com/article/slv-revenue-fell-14-and-net-loss-widened-as-biotech-demand-dropped-but-drug-deve-44b2d4b9fcc80835PharmaRadar360en2026-09-18T04:55:00.000ZSLV: Revenue fell 14% and net loss widened as biotech demand dropped, but Drug Development grew 16%https://www.pharmaradar360.com/article/ultragenyx-shares-rise-after-hours-following-fda-approval-ultragenyx-pharmaceuti-4517cfdb85b67294PharmaRadar360en2026-09-18T04:26:40.000ZUltragenyx Shares Rise After Hours Following FDA Approval - Ultragenyx Pharmaceutical (NASDAQ:RARE)https://www.pharmaradar360.com/article/scientists-restore-a-brain-protein-and-reverse-signs-of-aging-in-mice-e17168fca74ee1f1PharmaRadar360en2026-09-18T04:25:45.000ZScientists restore a brain protein and reverse signs of aging in micehttps://www.pharmaradar360.com/article/characteristics-of-low-voltage-zones-in-patients-with-heart-failure-with-preserv-5bb4200b0c0df75ePharmaRadar360en2026-09-18T04:03:44.000ZCharacteristics of Low‐Voltage Zones in Patients With Heart Failure With Preserved Ejection Fractionhttps://www.pharmaradar360.com/article/ozempic-can-change-your-body-can-it-change-your-life-d702a2323ab8162ePharmaRadar360en2026-09-18T03:52:09.000ZOzempic can change your body. Can it change your life?https://www.pharmaradar360.com/article/dr-reddy-s-labs-agrees-to-licensing-deal-with-gilead-for-once-yearly-lenacapavir-c6e21fe407ab9575PharmaRadar360en2026-09-18T03:38:34.000ZDr. Reddy's Labs Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIVhttps://www.pharmaradar360.com/article/mumbai-s-olympia-coffee-house-where-christopher-nolan-stopped-for-chai-loses-lic-bb4065e6955e1adcPharmaRadar360en2026-09-18T03:35:10.000ZMumbai's Olympia Coffee House, where Christopher Nolan stopped for chai, loses licencehttps://www.pharmaradar360.com/article/food-safety-crackdown-fda-suspends-licences-of-seven-mumbai-establishments-1bc5a4018c01d902PharmaRadar360en2026-09-18T03:11:00.000ZFood safety crackdown: FDA suspends licences of seven Mumbai establishmentshttps://www.pharmaradar360.com/article/51cc077bbc6c89d0PharmaRadar360en2026-09-18T03:01:15.000Z上部尿路（腎盂・尿管）がん術後の膀胱内再発予防に ピラルビシン膀注療法が有効であることを証明https://www.pharmaradar360.com/article/shinsa-samd-page-updated-guide-revised-seminar-videos-and-materials-published-co-619e30c9b864d6f8PharmaRadar360en2026-09-18T03:00:00.000Z[SHINSA]SaMD page updated (guide revised, seminar videos and materials published, consultation schedule updated)https://www.pharmaradar360.com/article/fda-suspends-cafe-mondegar-licence-over-food-safety-lapses-wider-crackdown-hits-dbf096ce62824842PharmaRadar360en2026-09-18T02:46:03.000ZFDA suspends Café Mondegar licence over food-safety lapses; wider crackdown hits Mumbai eaterieshttps://www.pharmaradar360.com/article/montana-s-new-rules-let-licensed-clinics-sell-drugs-that-cleared-only-phase-1-sa-9e447bd6f824af4ePharmaRadar360en2026-09-18T02:14:49.000ZMontana's New Rules Let Licensed Clinics Sell Drugs That Cleared Only Phase 1 Safety Testing to Paying Patientshttps://www.pharmaradar360.com/article/etfs-investing-in-shaanxi-panlong-pharmaceutical-group-co-ltd-class-a-stocks-474793fb82a908a6PharmaRadar360en2026-09-18T02:01:50.000ZETFs Investing in Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-3c6d6707f48c60b7PharmaRadar360en2026-09-18T02:00:00.000Z#PASSAPAROLA [21.09] 120 anni della Clinica Mangiagalli: celebriamo la culla d’Italiahttps://www.pharmaradar360.com/article/is-ultragenyx-pharmaceutical-rare-reasonable-after-its-fda-gene-therapy-approval-92ee3504e9cb0a80PharmaRadar360en2026-09-18T01:48:34.000ZIs Ultragenyx Pharmaceutical (RARE) Reasonable After Its FDA Gene Therapy Approval?https://www.pharmaradar360.com/article/bombay-high-court-asks-thane-restaurant-to-approach-food-safety-commissioner-ove-cb94d91d3cc4472dPharmaRadar360en2026-09-18T01:43:46.000ZBombay High Court asks Thane restaurant to approach Food Safety Commissioner over licence suspensionhttps://www.pharmaradar360.com/article/simulations-plus-expands-fda-adoption-of-admet-predictor-with-new-licenses-for-t-e883165e7f599585PharmaRadar360en2026-09-18T01:26:35.000ZSimulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branchhttps://www.pharmaradar360.com/article/electra-amasses-350m-in-biotech-s-latest-big-ipo-978099deecfc2361PharmaRadar360en2026-09-18T01:16:16.000ZElectra amasses $350M in biotech’s latest big IPOhttps://www.pharmaradar360.com/article/exclusive-astrazeneca-s-new-breast-cancer-drug-etracama-to-enter-korea-4a59ef93e0c56fb3PharmaRadar360en2026-09-18T00:50:46.000Z[Exclusive] AstraZeneca's New Breast Cancer Drug Etracama to Enter Koreahttps://www.pharmaradar360.com/article/12-tucsco-10-6-c99883a9f629ce01PharmaRadar360en2026-09-18T00:43:04.000Z第12回 東北大学ケアサイエンス共創センター（TUCSCO）セミナー開催のお知らせ（10/6開催）https://www.pharmaradar360.com/article/electra-s-350m-ipo-will-help-it-become-a-commercial-biotech-64654e6782d6b4d8PharmaRadar360en2026-09-18T00:43:00.000ZElectra’s $350M IPO will help it become a commercial biotechhttps://www.pharmaradar360.com/article/area-biotech-looks-ahead-7f2eaf55a0c8b74aPharmaRadar360en2026-09-18T00:19:00.000ZArea biotech looks aheadhttps://www.pharmaradar360.com/article/exclusive-retail-investors-buy-68-3b-won-in-sejong-medical-c5ee1465e913cc8fPharmaRadar360en2026-09-18T00:14:45.000ZExclusive: Retail Investors Buy 68.3B Won in Sejong Medicalhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-dd6239a9df91643dPharmaRadar360en2026-09-18T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/a-universal-visual-foundation-model-for-computational-cytopathology-d4d82831813740f5PharmaRadar360en2026-09-18T00:00:00.000ZA universal visual foundation model for computational cytopathologyhttps://www.pharmaradar360.com/article/serotonin-neurons-in-the-dorsal-raphe-control-food-craving-like-behavior-during-9b1cc1d30ce78bfdPharmaRadar360en2026-09-18T00:00:00.000ZSerotonin neurons in the dorsal raphe control food-craving-like behavior during pregnancy in micehttps://www.pharmaradar360.com/article/reciprocal-connections-dynamically-build-consensus-between-neocortical-areas-2904d1c3185e72a1PharmaRadar360en2026-09-18T00:00:00.000ZReciprocal connections dynamically build consensus between neocortical areashttps://www.pharmaradar360.com/article/two-parallel-neural-ectoderm-progenitors-contribute-to-the-developing-brain-27601ed7284656ccPharmaRadar360en2026-09-18T00:00:00.000ZTwo parallel neural ectoderm progenitors contribute to the developing brainhttps://www.pharmaradar360.com/article/chinese-companies-doubled-down-on-science-after-us-tech-restrictions-f5dc675196375a6ePharmaRadar360en2026-09-18T00:00:00.000ZChinese companies doubled down on science after US tech restrictionshttps://www.pharmaradar360.com/article/cognitive-resilience-helps-to-predict-alzheimer-s-dementia-61ec2e4b02e7618bPharmaRadar360en2026-09-18T00:00:00.000ZCognitive resilience helps to predict Alzheimer’s dementiahttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-99468576d4475ecdPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-0cd044981af5ad1fPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-8dd79c3a6f6e87edPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-62516a983397efc4PharmaRadar360en2026-09-18T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-37d5d8d5c2c18251PharmaRadar360en2026-09-18T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-24ca4672ffc8689dPharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2c167272dd414ca5PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-01f8759d83e0ece0PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-3c0ef826ba0e428bPharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-089df69bf082a363PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-26a72c8773f961bfPharmaRadar360en2026-09-18T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-30139f173ab191c4PharmaRadar360en2026-09-18T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-4daed0de11c9d6a0PharmaRadar360en2026-09-18T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-626670b9461fce6dPharmaRadar360en2026-09-18T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-6091ed1340d56d14PharmaRadar360en2026-09-18T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/electronic-submission-template-for-medical-device-premarket-approval-application-84868d5f9c7d515fPharmaRadar360en2026-09-18T00:00:00.000ZElectronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availabilityhttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-604ead149a445115PharmaRadar360en2026-09-18T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/biosimilar-user-fee-act-iii-future-needs-in-the-development-of-interchangeable-p-fe5a68d526ec88a9PharmaRadar360en2026-09-18T00:00:00.000ZBiosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Documenthttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-amended-notice-of-meeting-dcb583623cf5f6f4PharmaRadar360en2026-09-18T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-post-award-reporting-requirements-inc-48f728e96892f8f4PharmaRadar360en2026-09-18T00:00:00.000ZProposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)https://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-phs-applications-and-pre-award-report-45801451bb9edd47PharmaRadar360en2026-09-18T00:00:00.000ZProposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)https://www.pharmaradar360.com/article/notice-of-supplemental-funding-delta-region-community-health-systems-development-8a467900dbe269e1PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, Delta Region Community Health Systems Development Programhttps://www.pharmaradar360.com/article/healthy-start-self-measured-blood-pressure-monitoring-9a807fe7b2052867PharmaRadar360en2026-09-18T00:00:00.000ZHealthy Start Self-Measured Blood Pressure Monitoringhttps://www.pharmaradar360.com/article/infant-toddler-court-program-national-resource-center-87bdf4a836c3d8dbPharmaRadar360en2026-09-18T00:00:00.000ZInfant-Toddler Court Program-National Resource Centerhttps://www.pharmaradar360.com/article/target-animal-safety-evaluation-for-veterinary-monoclonal-antibody-products-draf-c6d6364c139b35dePharmaRadar360en2026-09-18T00:00:00.000ZTarget Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-library-of-medicine-notice-of-partially-closed-meeting-4cae51d99da667c3PharmaRadar360en2026-09-18T00:00:00.000ZNational Library of Medicine; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-3df8df59fcecf4b6PharmaRadar360en2026-09-18T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-amended-notice-of-meeting-ce1fbb114382a049PharmaRadar360en2026-09-18T00:00:00.000ZNational Center for Advancing Translational Sciences; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-national-rural-health-policy-community-and-collab-d1edde2289a9483fPharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, National Rural Health Policy, Community, and Collaboration Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-national-rural-health-information-clearinghouse-p-80273b101abb5b18PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, National Rural Health Information Clearinghouse Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-residency-planning-and-development-technica-bad78a3fbc8146b7PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding; Rural Residency Planning and Development Technical Assistance Programhttps://www.pharmaradar360.com/article/vill-forbattra-varden-vid-kronisk-njursjukdom-da50b1e1d961632cPharmaRadar360en2026-09-18T00:00:00.000ZVill förbättra vården vid kronisk njursjukdomhttps://www.pharmaradar360.com/article/han-breddar-sin-traumaforskning-med-stod-fran-forskar-at-48a89c1bf1f7d034PharmaRadar360en2026-09-18T00:00:00.000ZHan breddar sin traumaforskning med stöd från forskar-AThttps://www.pharmaradar360.com/article/erc-utmarkelse-uppmarksammar-allmanhetens-engagemang-kring-beroring-och-kittligh-bbd80f690deec459PharmaRadar360en2026-09-18T00:00:00.000ZERC-utmärkelse uppmärksammar allmänhetens engagemang kring beröring och kittlighethttps://www.pharmaradar360.com/article/pharmacists-perspectives-on-generative-artificial-intelligence-tools-in-pharmacy-9364bf8b6a1b9432PharmaRadar360en2026-09-18T00:00:00.000ZPharmacists’ perspectives on generative artificial intelligence tools in pharmacy practice and pharmacy educationhttps://www.pharmaradar360.com/article/practice-tips-for-successful-point-of-care-testing-programs-in-pharmacies-a53ecfbdb2e94510PharmaRadar360en2026-09-18T00:00:00.000ZPractice tips for successful point-of-care testing programs in pharmacieshttps://www.pharmaradar360.com/article/integrating-artificial-intelligence-across-the-cancer-drug-discovery-pipeline-us-d7efd9830701ac32PharmaRadar360en2026-09-18T00:00:00.000ZIntegrating artificial intelligence across the cancer drug discovery pipeline using a design-test-refine workflowhttps://www.pharmaradar360.com/article/pharmaco-multiomics-in-major-depressive-disorder-a-narrative-review-and-proposed-42e75faf60364346PharmaRadar360en2026-09-18T00:00:00.000ZPharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depressionhttps://www.pharmaradar360.com/article/factors-associated-with-clinical-research-participation-among-medicare-beneficia-b7de054f5c62fdebPharmaRadar360en2026-09-18T00:00:00.000ZFactors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United Stateshttps://www.pharmaradar360.com/article/from-benchmarking-to-global-leadership-singapore-s-health-sciences-authority-s-j-c9dff2d33578c9ddPharmaRadar360en2026-09-18T00:00:00.000ZFrom benchmarking to global leadership: Singapore’s health sciences authority’s journey to WHO maturity level 4 and WHO-Listed Authority status for medicineshttps://www.pharmaradar360.com/article/a-narrative-review-of-emerging-chemoprotective-agents-for-chemotherapy-induced-t-0a67f03191c1e550PharmaRadar360en2026-09-18T00:00:00.000ZA narrative review of emerging chemoprotective agents for chemotherapy-induced toxicity: nanoformulated natural products, dual COX-2/TNF-α inhibitors, and Nrf2 modulatorshttps://www.pharmaradar360.com/article/the-clinical-trial-landscape-of-bispecific-antibodies-in-non-small-cell-lung-can-bcb034023b34aa44PharmaRadar360en2026-09-18T00:00:00.000ZThe clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategieshttps://www.pharmaradar360.com/article/a-systems-microbiology-framework-for-reproducible-multi-dataset-omics-integratio-b779bce51648b197PharmaRadar360en2026-09-18T00:00:00.000ZA systems microbiology framework for reproducible multi-dataset omics integration with application to long COVIDhttps://www.pharmaradar360.com/article/exploring-traditional-chinese-medicine-to-enhance-the-efficacy-and-reduce-toxici-f47001b561f23943PharmaRadar360en2026-09-18T00:00:00.000ZExploring traditional Chinese medicine to enhance the efficacy and reduce toxicity of immunotherapy for non-small cell lung cancer from the perspective of “spleen deficiency”: a trial protocol for mechanism and clinical evidencehttps://www.pharmaradar360.com/article/bibliometric-and-clinical-trial-landscape-of-hepatoblastoma-2000-2024-a-multi-da-82994bbd094b43d4PharmaRadar360en2026-09-18T00:00:00.000ZBibliometric and clinical trial landscape of hepatoblastoma (2000–2024): a multi-database analysis of global researchhttps://www.pharmaradar360.com/article/method-development-validation-and-estimation-of-single-synthetic-drug-tafamidis-6c0d9c088549a9f2PharmaRadar360en2026-09-18T00:00:00.000ZMethod Development, Validation and Estimation of Single Synthetic Drug Tafamidis by RP-HPLC and Green Analysis in API Form and Pharmaceutical Dosage Formhttps://www.pharmaradar360.com/article/bacteriological-quality-of-pharmaceutical-effluents-in-awka-nigeria-37de73039abf6f90PharmaRadar360en2026-09-18T00:00:00.000ZBacteriological Quality of Pharmaceutical Effluents in Awka, Nigeriahttps://www.pharmaradar360.com/article/effectiveness-and-safety-of-screening-colonoscopy-in-adults-aged-75-years-and-ol-6d12f15e1391ea8cPharmaRadar360en2026-09-18T00:00:00.000ZEffectiveness and safety of screening colonoscopy in adults aged 75 years and older: a retrospective cohort study from Koreahttps://www.pharmaradar360.com/article/the-role-of-curcumin-in-neurogenesis-and-neuroprotection-in-alzheimer-s-disease-4243af857122205aPharmaRadar360en2026-09-18T00:00:00.000ZThe Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidencehttps://www.pharmaradar360.com/article/opioid-management-for-the-primary-care-physician-a-practical-guideline-based-cli-170f2da712920c3fPharmaRadar360en2026-09-18T00:00:00.000ZOpioid Management for the Primary Care Physician: A Practical, Guideline-Based Clinical Reviewhttps://www.pharmaradar360.com/article/nanocarriers-for-targeted-drug-delivery-in-cancer-therapy-innovations-and-challe-1c2dc318af7f590fPharmaRadar360en2026-09-18T00:00:00.000ZNanocarriers for Targeted Drug Delivery in Cancer Therapy: Innovations and Challengeshttps://www.pharmaradar360.com/article/dual-attention-ensemble-residual-learning-for-robust-diabetic-retinopathy-classi-633f8b4a39b678e6PharmaRadar360en2026-09-18T00:00:00.000ZDual-Attention Ensemble Residual Learning for Robust Diabetic Retinopathy Classification under Class Imbalancehttps://www.pharmaradar360.com/article/hand-function-and-oral-hygiene-performance-among-children-with-down-syndrome-a-c-ede1867ad511fb59PharmaRadar360en2026-09-18T00:00:00.000ZHand Function and Oral Hygiene Performance among Children with Down Syndrome: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/impact-of-cardiopulmonary-bypass-duration-on-intensive-care-and-hospital-length-15f8968488fed16dPharmaRadar360en2026-09-18T00:00:00.000ZImpact of Cardiopulmonary Bypass Duration on Intensive Care and Hospital Length of Stay in Coronary Artery Bypass Graftinghttps://www.pharmaradar360.com/article/the-effect-of-retrograde-autologous-priming-on-hematocrit-trajectory-and-transfu-5d9c48524efc7152PharmaRadar360en2026-09-18T00:00:00.000ZThe Effect of Retrograde Autologous Priming on Hematocrit Trajectory and Transfusion Requirement in Isolated Coronary Artery Bypass Surgeryhttps://www.pharmaradar360.com/article/aquagenic-palmoplantar-keratoderma-clinical-histopathological-and-ultrastructura-f28fff81510d6c3bPharmaRadar360en2026-09-18T00:00:00.000ZAquagenic palmoplantar keratoderma: Clinical, histopathological, and ultrastructural features in a 54-year-old manhttps://www.pharmaradar360.com/article/combination-therapy-of-biologic-and-non-biologic-systemic-agents-in-psoriasis-a-eb16a4d585839d3aPharmaRadar360en2026-09-18T00:00:00.000ZCombination therapy of biologic and non-biologic systemic agents in psoriasis: A narrative review of real-world evidence and clinical positioninghttps://www.pharmaradar360.com/article/the-neurological-burden-of-cirrhosis-a-comprehensive-clinical-review-of-mechanis-387c5cf15a238ed8PharmaRadar360en2026-09-18T00:00:00.000ZThe neurological burden of cirrhosis: a comprehensive clinical review of mechanisms, diagnosis, and managementhttps://www.pharmaradar360.com/article/xinshuaifang-improves-oxidative-stress-injury-and-myocardial-remodeling-in-acute-ea34efe2d9af33f7PharmaRadar360en2026-09-18T00:00:00.000ZXinshuaifang improves oxidative stress injury and myocardial remodeling in acute heart failure: Association with the gut-heart axishttps://www.pharmaradar360.com/article/dencichine-ameliorates-hepatic-fibrosis-by-modulating-the-pi3k-akt-signaling-pat-1feafa88df28df14PharmaRadar360en2026-09-18T00:00:00.000ZDencichine ameliorates hepatic fibrosis by modulating the PI3K/AKT signaling pathway in cellular and murine modelshttps://www.pharmaradar360.com/article/bmscs-promote-apoptosis-in-glioma-cells-by-inhibiting-stat3-phosphorylation-b0ab18bf9d391818PharmaRadar360en2026-09-18T00:00:00.000ZBMSCs promote apoptosis in glioma cells by inhibiting STAT3 phosphorylationhttps://www.pharmaradar360.com/article/artificial-intelligence-for-sleep-disordered-breathing-a-taxonomy-of-methods-dat-4212fb2e9998d4f0PharmaRadar360en2026-09-18T00:00:00.000ZArtificial intelligence for sleep-disordered breathing: a taxonomy of methods, data modalities, and clinical applicationshttps://www.pharmaradar360.com/article/appropriateness-of-antibiotic-prescribing-in-dental-practice-results-of-two-clin-9e717dd8a6e0113dPharmaRadar360en2026-09-18T00:00:00.000ZAppropriateness of antibiotic prescribing in dental practice: results of two clinical audits conducted at a university hospitalhttps://www.pharmaradar360.com/article/mechanism-aware-and-safety-validated-ai-for-drug-repurposing-a-critical-review-a-fe666815e2b4145aPharmaRadar360en2026-09-18T00:00:00.000ZMechanism-aware and safety-validated AI for drug repurposing: a critical review and translational pharmacology frameworkhttps://www.pharmaradar360.com/article/temporal-and-clinical-heterogeneity-of-double-m-protein-multiple-myeloma-diagnos-c674cc6b45f5fa7fPharmaRadar360en2026-09-18T00:00:00.000ZTemporal and clinical heterogeneity of double M-protein multiple myeloma: diagnostic and treatment-emergent phenotypeshttps://www.pharmaradar360.com/article/effect-of-antenatal-breast-milk-expression-or-postnatal-dietary-intervention-on-8cf881177dc218d1PharmaRadar360en2026-09-18T00:00:00.000ZEffect of antenatal breast milk expression or postnatal dietary intervention on breastfeeding outcomes and human milk composition in women with excess weight: protocol for the Ready, Set, Nourish study, a randomized controlled trialhttps://www.pharmaradar360.com/article/study-protocol-for-a-randomized-controlled-trial-comparing-penetrating-needling-1ca63ddbb2ae5d59PharmaRadar360en2026-09-18T00:00:00.000ZStudy protocol for a randomized controlled trial comparing penetrating needling and cognitive behavioral therapy for subjective tinnitushttps://www.pharmaradar360.com/article/sacituzumab-govitecan-in-metastatic-breast-cancer-a-systematic-review-and-meta-a-9e64e28209a31e7bPharmaRadar360en2026-09-18T00:00:00.000ZSacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safetyhttps://www.pharmaradar360.com/article/multidimensional-efficacy-characterization-of-xeligekimab-in-moderate-to-severe-54a1dbdb991fe995PharmaRadar360en2026-09-18T00:00:00.000ZMultidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trialhttps://www.pharmaradar360.com/article/non-guideline-compliant-prescriptions-of-benzodiazepines-and-z-drugs-effects-of-c82e1f698d7a330bPharmaRadar360en2026-09-18T00:00:00.000ZNon-guideline—compliant prescriptions of benzodiazepines and Z drugs: Effects of social norm feedback. A randomized controlled trialhttps://www.pharmaradar360.com/article/soluble-urokinase-type-plasminogen-activator-receptor-in-glomerular-disease-a-ma-e62ed0c5b157c549PharmaRadar360en2026-09-18T00:00:00.000ZSoluble urokinase-type plasminogen activator receptor in glomerular disease: a marker of activity or renal vulnerability?https://www.pharmaradar360.com/article/high-flow-nasal-cannula-in-adult-acute-care-physiological-mechanisms-clinical-ev-8f7e270a8cc693dcPharmaRadar360en2026-09-18T00:00:00.000ZHigh-Flow Nasal Cannula in Adult Acute Care: Physiological Mechanisms, Clinical Evidence, and Persistent Misconceptionshttps://www.pharmaradar360.com/article/oxford-nanopore-based-genomic-characterization-of-macrolide-resistance-in-clinic-b0635c7940c6e532PharmaRadar360en2026-09-18T00:00:00.000ZOxford Nanopore-Based Genomic Characterization of Macrolide Resistance in Clinical &lt;em&gt;Streptococcus pyogenes&lt;/em&gt; Isolateshttps://www.pharmaradar360.com/article/nucleic-acids-in-medicinal-plants-and-their-pharmaceutical-potential-5a69fb06fb585d6aPharmaRadar360en2026-09-18T00:00:00.000ZNucleic acids in medicinal plants and their pharmaceutical potentialhttps://www.pharmaradar360.com/article/diagnostic-value-of-urinary-albumin-creatinine-ratio-in-predicting-vision-threat-11c3ec9b9f2d15fcPharmaRadar360en2026-09-18T00:00:00.000ZDiagnostic value of urinary albumin creatinine ratio in predicting vision-threatening diabetic retinopathy in patients with diabetes: a systematic review and Meta-analysishttps://www.pharmaradar360.com/article/visual-and-accommodative-outcomes-after-femtosecond-lasik-with-and-without-monov-8f815f409c403df3PharmaRadar360en2026-09-18T00:00:00.000ZVisual and accommodative outcomes after femtosecond LASIK with and without monovision in patients over 40 yearshttps://www.pharmaradar360.com/article/collaborative-clinical-research-ethics-and-regulatory-governance-in-sub-saharan-a80d218f6a293c6dPharmaRadar360en2026-09-18T00:00:00.000ZCollaborative clinical research ethics and regulatory governance in Sub-Saharan Africa: Gaps, challenges and implicationshttps://www.pharmaradar360.com/article/saikosaponin-d-ameliorates-non-alcoholic-steatohepatitis-by-inhibiting-sting-med-d926f3f53f604836PharmaRadar360en2026-09-18T00:00:00.000ZSaikosaponin D Ameliorates Non-alcoholic Steatohepatitis by Inhibiting STING-Mediated Macrophage M1 Polarization in Micehttps://www.pharmaradar360.com/article/pubertal-delay-in-patients-with-paternally-derived-15q11-2-q13-duplication-syndr-97e9e561d7acd17bPharmaRadar360en2026-09-18T00:00:00.000ZPubertal delay in patients with paternally derived 15q11.2–q13 duplication syndrome and <i>MKRN3</i> overexpressionhttps://www.pharmaradar360.com/article/degradation-of-pharmaceutical-pollutants-in-wastewater-via-cellulose-microsphere-8720e55e1d533a4bPharmaRadar360en2026-09-18T00:00:00.000ZDegradation of Pharmaceutical Pollutants in Wastewater via Cellulose Microspherehttps://www.pharmaradar360.com/article/ai-driven-wearable-gadgets-for-personalization-of-drug-therapy-in-human-and-vete-ad56ba1a0ef26dd0PharmaRadar360en2026-09-18T00:00:00.000ZAI-Driven Wearable Gadgets for Personalization of Drug Therapy in Human and Veterinary Medicinehttps://www.pharmaradar360.com/article/leveraging-community-health-workers-for-the-promotion-of-breast-cancer-awareness-755600d79ec1f2d3PharmaRadar360en2026-09-18T00:00:00.000ZLeveraging community health workers for the promotion of Breast Cancer Awareness and Timely Help-Seeking Behaviour (BreCATH-B study), among underserved rural population in Kenya: a protocol for a hybrid type II cluster randomised controlled trialhttps://www.pharmaradar360.com/article/development-of-a-telerehabilitation-based-exercise-and-monitoring-program-and-it-be132e0c48930f0aPharmaRadar360en2026-09-18T00:00:00.000ZDevelopment of a telerehabilitation-based exercise and monitoring program and its effectiveness compared with a brochure-based home exercise program in patients with lumbar disc herniation: a randomized controlled trialhttps://www.pharmaradar360.com/article/correction-novel-covalent-cdk7-inhibitor-potently-induces-apoptosis-in-acute-mye-92e394580899b083PharmaRadar360en2026-09-18T00:00:00.000ZCorrection: Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclaxhttps://www.pharmaradar360.com/article/practice-variation-in-hospital-care-for-pelvic-organ-prolapse-and-urinary-incont-3d823e631c47eefePharmaRadar360en2026-09-18T00:00:00.000ZPractice variation in hospital care for pelvic organ prolapse and urinary incontinence: an analysis of specialists’ expectations, cross-sectional claims data, and the role of clinical guidelineshttps://www.pharmaradar360.com/article/clinical-and-financial-correlates-of-suicide-attempts-among-patients-with-gambli-02d0125d246d53edPharmaRadar360en2026-09-18T00:00:00.000ZClinical and financial correlates of suicide attempts among patients with gambling disorder: a retrospective studyhttps://www.pharmaradar360.com/article/randomized-phase-iii-trial-with-a-factorial-design-assessing-the-efficacy-and-sa-7ec071caeffd2817PharmaRadar360en2026-09-18T00:00:00.000ZRandomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocolhttps://www.pharmaradar360.com/article/drug-induced-phospholipidosis-following-haematopoietic-stem-cell-transplantation-ab9302e7e11d6b1dPharmaRadar360en2026-09-18T00:00:00.000ZDrug induced phospholipidosis following haematopoietic stem cell transplantation complicated by graft versus host disease: a small case serieshttps://www.pharmaradar360.com/article/powered-by-curiosity-the-emerge-model-for-advancing-clinical-research-leadership-97ddb4d925def0acPharmaRadar360en2026-09-18T00:00:00.000ZPowered by curiosity: the EMERGE model for advancing clinical research leadershiphttps://www.pharmaradar360.com/article/peri-plate-gas-detected-on-cervical-ct-as-an-exploratory-imaging-indicator-of-es-d84e1111a3a9cba7PharmaRadar360en2026-09-18T00:00:00.000ZPeri-Plate Gas Detected on Cervical CT as an Exploratory Imaging Indicator of Esophageal Perforation After Anterior Cervical Spine Surgeryhttps://www.pharmaradar360.com/article/general-dermatology-and-dermatology-in-primary-health-care-3ec6d2b585374c21PharmaRadar360en2026-09-18T00:00:00.000ZGeneral Dermatology and Dermatology in Primary Health Carehttps://www.pharmaradar360.com/article/effect-of-transcutaneous-auricular-vagus-nerve-stimulation-on-postoperative-gast-b4866bdcf6032b2fPharmaRadar360en2026-09-18T00:00:00.000ZEffect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trialhttps://www.pharmaradar360.com/article/worried-but-not-intending-when-expressive-suppression-dampens-the-motivational-r-bc40ea7445eb3adaPharmaRadar360en2026-09-18T00:00:00.000ZWorried but Not Intending: When Expressive Suppression Dampens the Motivational Role of Health Worry in Colorectal Cancer Screening Among Older Adultshttps://www.pharmaradar360.com/article/crispr-based-mediated-reactivation-of-fetal-hemoglobin-as-a-therapeutic-strategy-ba092edcd3d852cePharmaRadar360en2026-09-18T00:00:00.000ZCRISPR-Based Mediated Reactivation of Fetal Hemoglobin as a Therapeutic Strategy for Hemoglobinopathies: Evidence from Preclinical to Clinical Trials in Sickle Cell Disease and β-Thalassemiahttps://www.pharmaradar360.com/article/biotech-in-the-bottle-regulatory-insights-on-genetically-modified-microorganisms-1653567a20408884PharmaRadar360en2026-09-18T00:00:00.000ZBiotech in the Bottle: Regulatory Insights on Genetically Modified Microorganisms in Fermented Beverages in Brazil and International Benchmarkshttps://www.pharmaradar360.com/article/transitional-atrioventricular-septal-defect-diagnostic-variability-and-its-clini-29af8aaaec811944PharmaRadar360en2026-09-18T00:00:00.000ZTransitional atrioventricular septal defect: diagnostic variability and its clinical significancehttps://www.pharmaradar360.com/article/a-hybrid-bilstm-transformer-model-for-drug-synergy-prediction-f1cf6f42f7410d30PharmaRadar360en2026-09-18T00:00:00.000ZA hybrid BiLSTM transformer model for drug synergy predictionhttps://www.pharmaradar360.com/article/the-metabolic-epigenetic-axis-in-cardiovascular-disease-acylation-modifications-a9f5a8adcdf04488PharmaRadar360en2026-09-18T00:00:00.000ZThe Metabolic-Epigenetic Axis in Cardiovascular Disease: Acylation Modifications as Metabolic Sensors Linking Cardiac Metabolism to the Epigenomehttps://www.pharmaradar360.com/article/correction-expert-consensus-on-the-clinical-application-of-sulodexide-in-vascula-e5031bffd8f56f9fPharmaRadar360en2026-09-18T00:00:00.000ZCorrection: Expert Consensus on the Clinical Application of Sulodexide in Vascular Diseaseshttps://www.pharmaradar360.com/article/translating-deep-learning-innovations-into-clinical-medical-imaging-practice-eaa12e49e6dd3a61PharmaRadar360en2026-09-18T00:00:00.000ZTranslating deep learning innovations into clinical medical imaging practicehttps://www.pharmaradar360.com/article/factors-associated-with-current-frequent-and-multi-substance-use-among-adult-eve-a28e96d8b4e51e85PharmaRadar360en2026-09-18T00:00:00.000ZFactors associated with current, frequent, and multi-substance use among adult ever-users: a cross-sectional analysis of the 2024 National Survey on Drug Use and Healthhttps://www.pharmaradar360.com/article/hyperadrenergic-and-neuropathic-features-based-on-clinical-autonomic-testing-in-6c45958fcb4f3502PharmaRadar360en2026-09-18T00:00:00.000ZHyperadrenergic and neuropathic features based on clinical autonomic testing in individuals with POTS: an observational cross-sectional studyhttps://www.pharmaradar360.com/article/heliotropium-indicum-protects-against-estradiol-benzoate-induced-endometrial-hyp-4151ed057f65fcf8PharmaRadar360en2026-09-18T00:00:00.000ZHeliotropium indicum protects against estradiol benzoate-induced endometrial hyperplasia in female Wistar ratshttps://www.pharmaradar360.com/article/selenium-nanoparticles-enhanced-testicular-thermoregulatory-mechanisms-by-modula-3fbecd66a2f53d28PharmaRadar360en2026-09-18T00:00:00.000ZSelenium nanoparticles enhanced testicular thermoregulatory mechanisms by modulating testicular dimensions and hemodynamics, and blood flow mediators for improving semen quality of heat-stressed Egyptian goatshttps://www.pharmaradar360.com/article/clinical-images-nasal-type-extranodal-natural-killer-t-cell-lymphoma-mimicking-a-7fe393f29eb26cc7PharmaRadar360en2026-09-18T00:00:00.000ZClinical Images: Nasal‐type extranodal natural killer/T cell lymphoma mimicking antineutrophil cytoplasmic antibody–associated vasculitishttps://www.pharmaradar360.com/article/the-complexities-of-340b-rebate-tracking-345d5ee106e9a4f8PharmaRadar360en2026-09-17T23:38:34.000ZThe Complexities of 340B Rebate Trackinghttps://www.pharmaradar360.com/article/padcevtm-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-receives-8cf462a80b8a5d5cPharmaRadar360en2026-09-17T23:30:00.000ZPADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Adults with Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/russia-s-strikes-on-pharmaceutical-warehouses-threaten-ukrainians-access-to-medi-1481cd7f4bb09f30PharmaRadar360en2026-09-17T23:10:32.000ZRussia’s strikes on pharmaceutical warehouses threaten Ukrainians’ access to medicineshttps://www.pharmaradar360.com/article/emerging-biotech-companies-pitch-at-5th-annual-biodiscovery-summit-685693dd844a95e0PharmaRadar360en2026-09-17T23:06:00.000ZEmerging biotech companies pitch at 5th annual Biodiscovery summithttps://www.pharmaradar360.com/article/scientists-map-hidden-protein-network-that-helps-red-blood-cells-adapt-to-oxygen-7afbbb0fc95ddfd1PharmaRadar360en2026-09-17T22:07:16.000ZScientists Map Hidden Protein Network That Helps Red Blood Cells Adapt to Oxygenhttps://www.pharmaradar360.com/article/icb-homenageia-luiz-eurico-nasciutti-e-da-nome-do-professor-a-auditorio-7e639652208cc3c8PharmaRadar360en2026-09-17T22:06:22.000ZICB homenageia Luiz Eurico Nasciutti e dá nome do professor a auditóriohttps://www.pharmaradar360.com/article/these-biotech-stocks-are-cheap-based-on-1-fundamental-measure-815f0f905b0e25d8PharmaRadar360en2026-09-17T21:53:25.000ZThese Biotech Stocks Are Cheap Based On 1 Fundamental Measurehttps://www.pharmaradar360.com/article/convergence-eu-officials-tout-pending-pharmaceutical-reforms-7ec250273dd2050aPharmaRadar360en2026-09-17T21:30:00.000ZConvergence: EU officials tout pending pharmaceutical reformshttps://www.pharmaradar360.com/article/us-regulators-urge-more-research-on-testosterone-therapy-for-women-as-experts-de-80bb0693f610f163PharmaRadar360en2026-09-17T21:20:32.000ZUS regulators urge more research on testosterone therapy for women as experts debate benefits, riskshttps://www.pharmaradar360.com/article/experts-urge-fda-to-set-clear-safety-and-access-standards-for-psychedelic-drugs-0a2c211f558a4086PharmaRadar360en2026-09-17T21:17:34.000ZExperts urge FDA to set clear safety and access standards for psychedelic drugs (September 14) By Reutershttps://www.pharmaradar360.com/article/israeli-ag-biotech-firm-sets-up-north-american-hq-in-indiana-e82697c880a79273PharmaRadar360en2026-09-17T21:10:00.000ZIsraeli ag-biotech firm sets up North American HQ in Indianahttps://www.pharmaradar360.com/article/how-to-use-patient-feedback-in-clinical-trial-design-7307a00bb66a4178PharmaRadar360en2026-09-17T20:55:35.000ZHow to Use Patient Feedback in Clinical Trial Designhttps://www.pharmaradar360.com/article/the-pharmaceutical-industry-has-seven-years-to-solve-a-12-digit-problem-2ce095089f5a385fPharmaRadar360en2026-09-17T20:36:35.000ZThe pharmaceutical industry has seven years to solve a 12-digit problemhttps://www.pharmaradar360.com/article/anmat-emitio-carta-de-cierre-por-la-subsanacion-de-los-incumplimientos-detectado-5e048f3571d027fbPharmaRadar360en2026-09-17T20:21:48.000ZANMAT emitió Carta de Cierre por la subsanación de los incumplimientos detectados en CSL Behring S.A.https://www.pharmaradar360.com/article/a-kidney-drug-cut-teens-urine-protein-by-75-versus-placebo-1fc57cd2c9a56347PharmaRadar360en2026-09-17T20:18:42.000ZA kidney drug cut teens’ urine protein by 75% versus placebohttps://www.pharmaradar360.com/article/jornada-en-conmemoracion-del-dia-mundial-de-la-prevencion-del-suicidio-en-la-unl-dfd3ffb3bbe8c879PharmaRadar360en2026-09-17T20:18:03.000ZJornada en conmemoración del Día Mundial de la Prevención del Suicidio en la UNLPhttps://www.pharmaradar360.com/article/phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the-american-so-5091818a62b05fe0PharmaRadar360en2026-09-17T20:18:01.000ZPhase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGNhttps://www.pharmaradar360.com/article/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provide-037241532935d25ePharmaRadar360en2026-09-17T20:17:32.000ZXenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Programhttps://www.pharmaradar360.com/article/the-shrinking-return-on-investment-for-nordic-innovation-1ab4bf8551082130PharmaRadar360en2026-09-17T20:09:25.000ZThe shrinking return on investment for Nordic innovationhttps://www.pharmaradar360.com/article/xenon-submits-a-seizure-drug-to-fda-while-pausing-new-depression-trial-enrollmen-ed814c8e3c5c404ePharmaRadar360en2026-09-17T20:01:00.000ZXenon submits a seizure drug to FDA while pausing new depression-trial enrollmenthttps://www.pharmaradar360.com/article/biolinerx-ltd-nasdaq-blrx-share-price-blrx-stock-news-blrx-share-price-updates-7f60262f5eff496bPharmaRadar360en2026-09-17T20:00:00.000ZBioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updateshttps://www.pharmaradar360.com/article/emerging-biotech-companies-pitch-at-5th-annual-biodiscovery-summit-bf6d2c55316ea44dPharmaRadar360en2026-09-17T19:49:30.000ZEmerging biotech companies pitch at 5th annual Biodiscovery summithttps://www.pharmaradar360.com/article/fda-approves-new-indication-for-kerendia-pharmexec-6d2c25c3e5f2cd54PharmaRadar360en2026-09-17T19:45:11.000ZFDA Approves New Indication for Kerendia | PharmExechttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-new-multiplex-immunofluorescence-tool-a-human-genome-datab-a5d3e08006cbc4b2PharmaRadar360en2026-09-17T19:39:50.000ZThe biotech bi-weekly: new multiplex immunofluorescence tool, a human genome database and funding for rapid molecular testinghttps://www.pharmaradar360.com/article/fda-approves-first-gene-therapy-for-pediatric-patients-with-sanfilippo-syndrome-4b753211a5d929e8PharmaRadar360en2026-09-17T19:37:13.000ZFDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type Ahttps://www.pharmaradar360.com/article/4-pharmaceutical-packaging-trends-to-know-a8bfd26f9dca5759PharmaRadar360en2026-09-17T19:33:56.000Z4 Pharmaceutical Packaging Trends To Knowhttps://www.pharmaradar360.com/article/17-09-il-policlinico-di-milano-si-illumina-di-arancione-per-la-giornata-nazional-4a1539b5441c3634PharmaRadar360en2026-09-17T19:23:00.000Z[17.09] Il Policlinico di Milano si illumina di arancione per la Giornata Nazionale della Sicurezza delle Curehttps://www.pharmaradar360.com/article/construction-industry-champions-heart-health-through-campaign-169f417446778731PharmaRadar360en2026-09-17T19:20:00.000ZConstruction industry champions heart health through campaignhttps://www.pharmaradar360.com/article/intermountain-health-and-utah-highway-safety-office-urge-parents-to-rethink-comm-8067c480bdd51a75PharmaRadar360en2026-09-17T19:14:23.000ZIntermountain Health and Utah Highway Safety Office Urge Parents to Rethink Common Car Seat Mistakeshttps://www.pharmaradar360.com/article/fda-approves-takeda-s-orzeyful-as-first-drug-to-treat-narcolepsy-type-1-cause-49d3fb93ffe19a13PharmaRadar360en2026-09-17T18:43:59.000ZFDA approves Takeda's ORZEYFUL as first drug to treat narcolepsy type 1 causehttps://www.pharmaradar360.com/article/roche-announces-grand-opening-of-its-innovation-center-boston-to-drive-advanceme-f51da51b1bf34aa9PharmaRadar360en2026-09-17T18:30:00.000ZRoche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseaseshttps://www.pharmaradar360.com/article/the-realities-of-china-s-prolific-biotech-rise-are-felt-at-fda-1795c883b63f206aPharmaRadar360en2026-09-17T18:27:00.000ZThe realities of China’s prolific biotech rise are felt at FDAhttps://www.pharmaradar360.com/article/virtual-biotech-framework-uses-ai-scientists-to-pursue-probe-drug-discovery-19244671a207ef09PharmaRadar360en2026-09-17T18:16:00.000Z‘Virtual Biotech’ Framework Uses AI Scientists to Pursue, Probe Drug Discoveryhttps://www.pharmaradar360.com/article/wegovy-for-children-under-12-sparks-obesity-debate-67a99e0bdea0cb68PharmaRadar360en2026-09-17T18:15:57.000ZWegovy for Children Under 12 Sparks Obesity Debatehttps://www.pharmaradar360.com/article/live-from-dc-can-the-fda-steer-clinical-trials-back-to-the-us-post-hoc-live-25792fcad212d192PharmaRadar360en2026-09-17T18:15:23.000ZLive from DC: Can the FDA steer clinical trials back to the US?｜Post-Hoc Livehttps://www.pharmaradar360.com/article/stricter-fda-norms-cast-shadow-on-ganesh-mandals-mahaprasad-plans-only-250-enrol-2c7c8c07d156ef63PharmaRadar360en2026-09-17T18:09:00.000ZStricter FDA norms cast shadow on Ganesh mandals’ Mahaprasad plans, only 250 enrolhttps://www.pharmaradar360.com/article/virtual-biotech-company-puts-thousands-of-ai-scientist-agents-to-work-on-drug-di-723a870ca063cacdPharmaRadar360en2026-09-17T18:04:39.000ZVirtual biotech company puts thousands of AI scientist agents to work on drug discoveryhttps://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-17T17:51:46.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/accelerated-research-increased-investment-signal-landmark-year-for-food-is-medic-037665fb995f5136PharmaRadar360en2026-09-17T17:30:00.000ZAccelerated research, increased investment signal landmark year for food is medicinehttps://www.pharmaradar360.com/article/transferencia-a-municipios-facultad-de-ciencias-exactas-25750730448c9187PharmaRadar360en2026-09-17T17:29:10.000ZTransferencia a Municipios — Facultad de Ciencias Exactashttps://www.pharmaradar360.com/article/iqhq-hands-vacant-biotech-building-back-to-lender-as-bay-area-life-sciences-slum-4369a9fe64919d18PharmaRadar360en2026-09-17T17:24:00.000ZIQHQ hands vacant biotech building back to lender as Bay Area life sciences slump drags onhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-gets-priority-review-can-zasocitinib-win-in-psoriasis-3598469b22effd81PharmaRadar360en2026-09-17T17:08:19.000ZTakeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?https://www.pharmaradar360.com/article/maryland-makes-its-case-as-a-model-for-u-s-biotech-supply-chain-security-3ddb3271125dc205PharmaRadar360en2026-09-17T16:57:15.000ZMaryland Makes Its Case as a Model for U.S. Biotech Supply Chain Securityhttps://www.pharmaradar360.com/article/frances-oldham-kelsey-the-pharmacologist-who-stopped-thalidomide-73c1c740e2953127PharmaRadar360en2026-09-17T16:52:14.000ZFrances Oldham Kelsey: The Pharmacologist Who Stopped Thalidomidehttps://www.pharmaradar360.com/article/why-is-novo-nordisk-stock-trading-higher-today-novo-nordisk-nyse-nvo-146fc47e146018acPharmaRadar360en2026-09-17T16:44:58.000ZWhy Is Novo Nordisk Stock Trading Higher Today? - Novo Nordisk (NYSE:NVO)https://www.pharmaradar360.com/article/altis-labs-raises-us-25-million-series-a-co-led-by-orbimed-to-accelerate-clinica-938f7b0684c81129PharmaRadar360en2026-09-17T16:44:46.000ZAltis Labs Raises US$25 Million Series A Co-Led by OrbiMed to Accelerate Clinical Development with AI Endpointshttps://www.pharmaradar360.com/article/amgen-targets-first-line-itp-market-with-new-phase-3-romiplostim-trial-b2b5a50b508a6418PharmaRadar360en2026-09-17T16:39:31.000ZAmgen Targets First-Line ITP Market With New Phase 3 Romiplostim Trialhttps://www.pharmaradar360.com/article/fda-eases-compounding-rules-for-preemie-nutrition-packs-as-supply-shortage-looms-8798c0cbcd5cf433PharmaRadar360en2026-09-17T16:34:00.000ZFDA eases compounding rules for preemie nutrition packs as supply shortage loomshttps://www.pharmaradar360.com/article/ideaya-biosciences-stock-gains-attention-as-ide-849-moves-toward-phase-3-d8645ee5bb43994fPharmaRadar360en2026-09-17T16:33:44.000ZIDEAYA Biosciences stock gains attention as IDE-849 moves toward Phase 3https://www.pharmaradar360.com/article/how-much-does-a-tms-machine-cost-pricing-and-total-cost-of-ownership-compared-fo-4d06c42d3d7ea456PharmaRadar360en2026-09-17T16:33:31.000ZHow Much Does a TMS Machine Cost? Pricing and Total Cost of Ownership Compared for Practiceshttps://www.pharmaradar360.com/article/a-biotech-company-had-268-million-in-cash-after-a-failed-drug-trial-it-announced-f6d2b2fc48d86112PharmaRadar360en2026-09-17T16:19:58.000ZA Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cuthttps://www.pharmaradar360.com/article/marlaina-goedel-marks-two-years-insulin-free-after-becoming-the-first-patient-in-c146a8c3d88155c5PharmaRadar360en2026-09-17T16:19:30.000ZMarlaina Goedel Marks Two Years Insulin-Free After Becoming the First Patient in Eledon’s Groundbreaking Islet Cell Transplant Trialhttps://www.pharmaradar360.com/article/inside-eledon-s-push-to-transform-type-1-diabetes-care-78d5e3a63d6b0ed6PharmaRadar360en2026-09-17T16:19:00.000ZInside Eledon’s Push to Transform Type 1 Diabetes Carehttps://www.pharmaradar360.com/article/the-eu-joint-clinical-assessment-turning-hta-reform-into-a-market-access-advanta-dd9e756bfa433d56PharmaRadar360en2026-09-17T16:14:21.000ZThe EU Joint Clinical Assessment: Turning HTA reform into a market access advantagehttps://www.pharmaradar360.com/article/north-immunology-joins-biotech-reverse-merger-boom-with-aethlon-deal-b8f9ff2d896dff1ePharmaRadar360en2026-09-17T16:09:10.000ZNorth Immunology joins biotech reverse merger boom with Aethlon dealhttps://www.pharmaradar360.com/article/fda-approves-snda-for-taletrectinib-in-ros1-nsclc-53ff6cb7f80eb90aPharmaRadar360en2026-09-17T16:07:34.000ZFDA Approves sNDA for Taletrectinib in ROS1+ NSCLChttps://www.pharmaradar360.com/article/ai-diagnoses-a-major-factor-in-allina-health-s-doctors-strike-23be44412a8b9da9PharmaRadar360en2026-09-17T15:56:36.000ZAI diagnoses a major factor in Allina Health's doctors strikehttps://www.pharmaradar360.com/article/the-challengers-why-it-will-be-hard-in-a-midterm-likely-to-herald-change-to-oust-97f56f6d2eef548ePharmaRadar360en2026-09-17T15:55:59.000ZThe Challengers: Why it will be hard, in a midterm likely to herald change, to oust a congressional incumbent in Minnesotahttps://www.pharmaradar360.com/article/inside-minnesota-s-sentencing-guidelines-why-fraud-cases-rarely-lead-to-prison-68d9f5fccba4cc1aPharmaRadar360en2026-09-17T15:55:24.000ZInside Minnesota’s sentencing guidelines: Why fraud cases rarely lead to prisonhttps://www.pharmaradar360.com/article/inside-your-health-vaccine-recommendations-091737b5dba58c68PharmaRadar360en2026-09-17T15:54:46.000ZInside Your Health: Vaccine recommendationshttps://www.pharmaradar360.com/article/northern-soy-marketing-welcoming-southeast-asian-soy-buyers-for-fourth-annual-cr-0f93f965c70c1661PharmaRadar360en2026-09-17T15:54:09.000ZNorthern Soy Marketing welcoming southeast Asian soy buyers for fourth annual Crop Tourhttps://www.pharmaradar360.com/article/students-explore-hmong-culture-through-gardening-program-483fe2ab61b687c4PharmaRadar360en2026-09-17T15:53:22.000ZStudents Explore Hmong Culture Through Gardening Programhttps://www.pharmaradar360.com/article/days-after-maharashtra-fda-revelation-medicine-safety-act-sought-to-prevent-expl-62dece922f3831a3PharmaRadar360en2026-09-17T15:34:45.000ZDays After Maharashtra FDA Revelation, Medicine Safety Act Sought To Prevent Exploitation Of Patientshttps://www.pharmaradar360.com/article/q-a-inside-the-ndc-12-transition-f8240ebebcaa2280PharmaRadar360en2026-09-17T15:34:12.000ZQ&A: Inside the NDC-12 Transitionhttps://www.pharmaradar360.com/article/there-s-a-biotech-stock-on-josh-brown-s-list-that-s-ignoring-the-market-noise-an-00acfc4984bf14efPharmaRadar360en2026-09-17T15:32:57.000ZThere's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higherhttps://www.pharmaradar360.com/article/a-new-mechanism-discovered-that-helps-cells-prevent-errors-during-dna-replicatio-799e041dbb008041PharmaRadar360en2026-09-17T15:25:10.000ZA new mechanism discovered that helps cells prevent errors during DNA replicationhttps://www.pharmaradar360.com/article/moving-forward-with-purpose-77635de00e54261ePharmaRadar360en2026-09-17T15:15:32.000ZMoving forward with purposehttps://www.pharmaradar360.com/article/5-rochester-leaders-advocate-for-health-and-raise-funds-critical-for-fighting-he-83ecf322ceaf42b9PharmaRadar360en2026-09-17T15:10:00.000Z5 Rochester leaders advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/patient-es-du-chu-vos-factures-et-leur-mode-de-transmission-evoluent-4dc4dbcbdd7a58d6PharmaRadar360en2026-09-17T15:01:40.000ZPatient·es du CHU : vos factures et leur mode de transmission évoluent !https://www.pharmaradar360.com/article/retour-sur-le-1eseminaire-prevenir-dedie-aux-professionnel-les-du-chu-2e56edc628cd51e6PharmaRadar360en2026-09-17T14:55:30.000ZRetour sur le 1eséminaire « Prévenir » dédié aux professionnel·les du CHUhttps://www.pharmaradar360.com/article/abbvie-to-present-phase-3-etentamig-results-and-data-from-broad-multiple-myeloma-29444dd186815626PharmaRadar360en2026-09-17T14:53:55.000ZAbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meetinghttps://www.pharmaradar360.com/article/3-maryland-leaders-advocate-for-health-and-raise-funds-critical-for-fighting-hea-ad7cc39c4825b3a6PharmaRadar360en2026-09-17T14:53:00.000Z3 Maryland leaders advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/classement-newsweek-gustave-roussy-premier-centre-de-lutte-contre-le-cancer-en-e-4e1ce4ca95c94eb3PharmaRadar360en2026-09-17T14:52:38.000ZClassement Newsweek : Gustave Roussy, premier centre de lutte contre le cancer en Europe, troisième mondialhttps://www.pharmaradar360.com/article/becas-internacionales-de-la-subsecretaria-de-relaciones-internacionales-e-interj-dfa8f436132d68d8PharmaRadar360en2026-09-17T14:45:50.000ZBecas internacionales de la Subsecretaría de Relaciones Internacionales e Interjurisdiccionales PBAhttps://www.pharmaradar360.com/article/the-escalator-legend-biotech-biomarin-turn-therapeutics-and-more-59a1bb9970ad70bePharmaRadar360en2026-09-17T14:43:54.000ZThe Escalator: Legend Biotech, BioMarin, Turn Therapeutics and morehttps://www.pharmaradar360.com/article/this-popular-fermented-food-may-help-flush-nanoplastics-from-the-body-95f0ba92fb6fd6ebPharmaRadar360en2026-09-17T14:42:52.000ZThis popular fermented food may help flush nanoplastics from the bodyhttps://www.pharmaradar360.com/article/southern-virginia-heart-walk-brings-community-businesses-together-to-fight-heart-f5b148de4b03b26bPharmaRadar360en2026-09-17T14:41:00.000ZSouthern Virginia Heart Walk brings community, businesses together to fight heart disease and strokehttps://www.pharmaradar360.com/article/subtle-medical-named-to-time-s-world-s-top-healthtech-companies-for-the-second-c-9311e95b20857983PharmaRadar360en2026-09-17T14:35:40.000ZSubtle Medical Named to TIME’s World’s Top HealthTech Companies for the Second Consecutive Yearhttps://www.pharmaradar360.com/article/intermountain-health-opens-grand-junction-physical-therapy-clinic-b0291a44cc83f8faPharmaRadar360en2026-09-17T14:34:59.000ZIntermountain Health Opens Grand Junction Physical Therapy Clinichttps://www.pharmaradar360.com/article/centanafadine-may-offer-second-line-option-for-patients-with-adhd-if-stimulants-3e160ac2fc5ea8b2PharmaRadar360en2026-09-17T14:34:43.000ZCentanafadine May Offer Second-Line Option for Patients With ADHD If Stimulants Failhttps://www.pharmaradar360.com/article/new-startup-to-test-psychedelic-like-drug-against-parkinson-s-symptom-b4ed51ead7a85a49PharmaRadar360en2026-09-17T14:34:39.000ZNew startup to test psychedelic-like drug against Parkinson’s symptomhttps://www.pharmaradar360.com/article/5th-circuit-panel-seems-skeptical-of-louisiana-abortion-pill-case-aa9c158dc8721073PharmaRadar360en2026-09-17T14:32:07.000Z5th Circuit panel seems skeptical of Louisiana abortion pill casehttps://www.pharmaradar360.com/article/measuring-excess-mortality-a-guide-to-the-main-reports-12c7784e1f020f77PharmaRadar360en2026-09-17T14:31:13.000ZMeasuring excess mortality: a guide to the main reportshttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharmaRadar360en2026-09-17T14:30:05.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831PharmaRadar360en2026-09-17T14:30:05.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1PharmaRadar360en2026-09-17T14:30:05.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/cardiac-arrest-survivors-sisters-advocate-for-health-and-raise-funds-critical-fo-88a18b7d57821017PharmaRadar360en2026-09-17T14:30:00.000ZCardiac arrest survivors, sisters advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/neuer-biodrucker-fur-die-plastisch-und-handchirurgische-klinik-7c40774901042ea9PharmaRadar360en2026-09-17T14:29:31.000ZNeuer Biodrucker für die Plastisch- und Handchirurgische Klinikhttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7PharmaRadar360en2026-09-17T14:17:28.000ZWorking for DHSChttps://www.pharmaradar360.com/article/pet-come-si-svolge-l-esame-3a1f061b28f6012bPharmaRadar360en2026-09-17T14:14:21.000ZPET: come si svolge l’esame?https://www.pharmaradar360.com/article/usz-erreicht-spitzenplatze-in-elf-fachbereichen-e640f37cd5d6e7b6PharmaRadar360en2026-09-17T14:12:58.000ZUSZ erreicht Spitzenplätze in elf Fachbereichenhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-20-september-2026-7353f08bd7424352PharmaRadar360en2026-09-17T14:09:56.000ZWeekly all-cause mortality surveillance: week ending 20 September 2026https://www.pharmaradar360.com/article/us-fda-eliminates-outdated-uv-filters-as-regulatory-modernization-continues-2732866e9bc52a42PharmaRadar360en2026-09-17T14:09:24.000ZUS FDA eliminates outdated UV filters as regulatory modernization continues.https://www.pharmaradar360.com/article/aquestive-resubmits-nda-for-sublingual-epinephrine-film-anaphylm-after-fda-crl-cbe278ad7206f20aPharmaRadar360en2026-09-17T14:05:06.000ZAquestive resubmits NDA for sublingual epinephrine film Anaphylm after FDA CRLhttps://www.pharmaradar360.com/article/biotech-company-receives-second-grant-to-develop-gene-therapy-for-afib-8bff45b3daa50406PharmaRadar360en2026-09-17T14:03:13.000ZBiotech company receives second grant to develop gene therapy for AFibhttps://www.pharmaradar360.com/article/psychedelic-definium-s-lsd-based-drug-meets-endpoints-in-gad-study-9946f77790c4ebafPharmaRadar360en2026-09-17T14:02:53.000ZPsychedelic: Definium’s LSD-based drug meets endpoints in GAD studyhttps://www.pharmaradar360.com/article/minister-of-state-for-social-care-and-mental-health-speech-on-dementia-4b19c9af5602321dPharmaRadar360en2026-09-17T14:01:58.000ZMinister of State for Social Care and Mental Health speech on dementiahttps://www.pharmaradar360.com/article/4-puget-sound-leaders-advocate-for-health-and-raise-funds-critical-for-fighting-228ecfcb192837c8PharmaRadar360en2026-09-17T14:00:00.000Z4 Puget Sound leaders advocate for health and raise funds critical for fighting heart disease and stroke